Loading institutional data...
Loading institutional data...
Institutional distribution: ownership decreased -1.73% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 30 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
3/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$8M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 9 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: -285%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 9 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $7M covers the $3M due within a year 2.8× over. Scheduled principal only (excludes interest & revolver draws). As of 2026-03-31 (10-Q).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~0.2% on $7M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Nothing notable to watch.
Where each multiple sits in its own 8-yr range · 38th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 8-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 58.3 | 48.4 | 49.7 | 25.4 | 18.8 | 17.5 | 15.0 | 13.2 |
| Gross Profit | 41.7 | 51.6 | 50.3 | 74.6 | 81.2 | 82.5 | 85.0 | 86.8 |
| R&D | 1255.5 | 414.3 | 120.2 | 46.5 | 64.2 | 33.2 | 9.4 | — |
| SG&A | 4280.3 | 1481.9 | 624.8 | 395.8 | 283.2 | 169.5 | 123.9 | 119.3 |
| Operating Income | -5494.1 | -1928.2 | -707.9 | -367.7 | -266.2 | -120.2 | -48.3 | -41.1 |
| Income Tax | 0.2 | 0.7 | -33.5 | -15.6 | -5.0 | -1.2 | -0.4 | 0.0 |
| Net Income | -5621.7 | -1888.8 | -672.5 | -315.9 | -257.9 | -117.5 | -47.2 | -43.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ECOR: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32.0M 100.0% | $25.2M 100.0% | $16.0M 100.0% | $8.6M 100.0% | $5.5M 100.0% | $3.5M 100.0% | $2.4M 100.0% | $993K 100.0% | $811K 100.0% |
| Cost of Revenue | $4.2M 13.2% | $3.8M 15.0% | $2.8M 17.5% | $1.6M 18.8% | $1.4M 25.4% | $1.7M 49.7% | $1.2M 48.4% | $579K 58.3% | $519K 63.9% |
| Gross Profit | $27.8M 86.8% | $21.4M 85.0% | $13.2M 82.5% | $7.0M 81.2% | $4.1M 74.6% | $1.8M 50.3% | $1.2M 51.6% | $414K 41.7% | $293K 36.1% |
| Research & Development | — | $2.4M 9.4% | $5.3M 33.2% | $5.5M 64.2% | $2.5M 46.5% | $4.2M 120.2% | $9.9M 414.3% | $12.5M 1255.5% | $7.8M 965.0% |
| Selling, General & Admin | $38.2M 119.3% | $31.2M 123.9% | $27.2M 169.5% | $24.3M 283.2% | $21.6M 395.8% | $21.8M 624.8% | $35.4M 1481.9% | $42.5M 4280.3% | $18.1M 2231.4% |
| Total Operating Expenses | $40.9M 127.8% | $33.6M 133.3% | $32.5M 202.7% | $29.9M 347.4% | $24.1M 442.3% | $26.5M 758.2% | $47.3M 1979.8% | $55.0M 5535.8% | $25.9M 3196.4% |
| Operating Income | -$13.2M -41.1% | -$12.2M -48.3% | -$19.3M -120.2% | -$22.9M -266.2% | -$20.0M -367.7% | -$24.7M -707.9% | -$46.1M -1928.2% | -$54.6M -5494.1% | -$25.6M -3160.3% |
| Interest Expense | $15K 0.0% | $18K 0.1% | — | $4K 0.0% | — | $341 0.0% | $3K 0.1% | — | $6.3M 775.9% |
| Other Income (Expense), net | -$810K -2.5% | $183K 0.7% | $249K 1.6% | $281K 3.3% | $2.0M 36.2% | $67K 1.9% | $958K 40.1% | -$1.2M -121.8% | -$10.4M -1279.7% |
| Pretax Income | -$14.0M -43.6% | -$12.0M -47.6% | -$19.0M -118.7% | -$22.6M -263.0% | -$18.1M -331.5% | -$24.7M -706.0% | -$45.1M -1888.1% | -$55.8M -5615.9% | -$36.0M -4440.0% |
| Income Tax Expense | $3K 0.0% | -$93K -0.4% | -$186K -1.2% | -$431K -5.0% | -$851K -15.6% | -$1.2M -33.5% | $18K 0.7% | $2K 0.2% | — |
| Net Income | -$14.0M -43.6% | -$11.9M -47.2% | -$18.8M -117.5% | -$22.2M -257.9% | -$17.2M -315.9% | -$23.5M -672.5% | -$45.1M -1888.8% | -$55.8M -5621.7% | -$35.8M -4410.9% |
| Per Share | |||||||||
| EPS (Basic) | $-1.65 | $-1.59 | $-3.42 | $-4.69 | $-4.36 | — | — | — | — |
| EPS (Diluted) | $-1.65 | $-1.59 | $-3.42 | $-4.69 | $-4.36 | — | — | — | — |
| Weighted Avg Shares (Basic) | 8K | 7K | 5.5M | 5K | 4K | — | — | — | — |
| Weighted Avg Shares (Diluted) | 8K | 7K | 5.5M | 5K | 4K | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ECOR | $91M | — | — | 2.8× | 27.2% | 86.8% | -43.6% | 817% | -285% | — | 29 |
Peers = companies sharing ECOR's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.